The US Food and Drug Administration (FDA) recently approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell ...

BEIJING, May 21, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...

SAN DIEGO -- Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and rituximab (Rituxan) resulted in a significant and clinically ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The US Food and Drug Administration has approved tafasitamab (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory (r/r) follicular lymphoma (FL).

Please provide your email address to receive an email when new articles are posted on . The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or ...

Incyte and MorphoSys have revealed that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for tafasitamab, an anti-CD19 antibody. Incyte and MorphoSys ...

Both sets of data were unveiled at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which was held earlier this month in a virtual format. Earlier this month, drugmakers unveiled ...

Please provide your email address to receive an email when new articles are posted on . In this video, Paolo Strati, MD, of The University of Texas MD Anderson Cancer Center, discusses quality of life ...

Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial. The clinical data supporting the addition of tafasitamab to lenalidomide ...

1.1 Tafasitamab with lenalidomide is not recommended, within its marketing authorisation, for treating relapsed or refractory diffuse large B‑cell lymphoma in adults who cannot have an autologous stem ...

At the recent American Society of Hematology (ASH) annual meeting, late-breaking phase III data demonstrated that adding tafasitamab (Monjuvi) to lenalidomide (Revlimid) and rituximab (Rituxan) ...